Managers / Q4 2025 · view latest →
TRV GP VI, LLC
CIK 0001990716 · 201 BROOKLINE AVE., BOSTON, MA, 02215 · 617-585-2000
Summary
Trv GP Vi, LLC reported $149M in U.S.-listed holdings across 3 positions for Q4 2025.
The portfolio is heavily concentrated: SEPN alone accounts for 79.0% of reported value.
The book was largely unchanged from Q3 2025.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 100.0% · $149M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SEPNSEPTERNA, INC. | HELD | +0 | 4.21M | +$38M | $117M |
| RAPPRAPPORT THERAPEUTICS, INC. | HELD | +0 | 969.2K | +$620,299 | $29M |
| TNGXTANGO THERAPEUTICS, INC. | HELD | +0 | 194.2K | +$89,320 | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | SEPNSEPTERNA, INC.history → | COM | 79.05% | $117M | 4.21M |
| 2 | RAPPRAPPORT THERAPEUTICS, INC.history → | COM | 19.80% | $29M | 969.2K |
| 3 | TNGXTANGO THERAPEUTICS, INC.history → | COM | 1.16% | $2M | 194.2K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $136M | 3 | May 7, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $149M | 3 | Feb 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $110M | 3 | Nov 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $64M | 4 | Aug 8, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $42M | 4 | May 9, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $117M | 4 | Feb 13, 2025 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.